EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evidence of trh and trh binding sites in human nonsecreting pituitary adenomas






Journal of Clinical Endocrinology & Metabolism 65(5): 1014-1019

Evidence of trh and trh binding sites in human nonsecreting pituitary adenomas

Immunoreactive TRH (IR-TRH) and TRH-binding sites were sought in nonsecreting pituitary adenomas. [3H]TRH bound specifically to cellular membranes from 11 of 12 such adenomas studied with a dissociation constant (Kd) of 50 .+-. 5 (.+-. SEM) nmol/L and a maximum number of binding sites of 76 .+-. 16 fmol/mg membrane protein (range, 32-229 fmol/mg protein). IR-TRH was detected in all 8 of the tumors in which it was sought. The identity of the IR-TRH WAS verified by high pressure liquid chromatography. The tumor IR-TRH concentration varied from 45-248 fmol/mg cell protein (mean, 109 .+-. 28 fmol/mg cell protein), about half that in normal human pituitary (229 .+-. 55 fmol/mg protein). There was no correlation between the number of binding sites and the IR-TRH content. The role of TRH in nonsecreting pituitary adenomas is unknown at this time.

(PDF 0-2 workdays service: $29.90)

Accession: 005411821



Related references

Evidence of thyrotropin-releasing hormone (TRH) and TRH-binding sites in human nonsecreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 65(5): 1014-1019, 1987

Evidence of high affinity binding sites for trh in human prolactin secreting pituitary adenomas. Comptes Rendus des Seances de l'Academie des Sciences Serie III Sciences de la Vie 296(1): 43-46, 1983

Dopaminergic binding sites in human pituitary adenomas other than prolactinomas. Hormone Research 19(2): 97-102, 1984

Epidermal growth factor-binding sites, present in normal human and rat pituitaries, are absent in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 65(2): 275-281, 1987

Five-year follow-up of nonsecreting pituitary adenomas. Archives of Otolaryngology--Head & Neck Surgery 121(3): 317-322, 1995

Presence of high-affinity binding sites for thyroliberin in human pituitary adenomas secreting prolactin. Comptes Rendus des Seances de L'academie des Sciences. Serie Iii, Sciences de la Vie 296(1): 43-46, 1983

Clinically nonsecreting pituitary adenomas in childhood and adolescence. Neurosurgery 42(4): 744-50; Discussion 750-1, 1998

Receptor and neuropeptide studies in nonsecreting pituitary adenomas. Faglia, G , Et Al (Ed ) International Congress Series, No 961 Pituitary Adenomas: New Trends in Basic And Clinical Research; 5th European Workshop on Pituitary Adenomas, Venice, Italy, March 17-20, X+395p Elsevier Science Publishers B V : Amsterdam, Netherlands; (Dist in The Usa And Canada By Elsevier Science Publishing Co , Inc : New York, New York, Usa) Illus 365-372, 1991

Evidence of pit 1 related dna binding proteins in diverse human pituitary adenomas. Journal of Endocrinology 132(SUPPL), 1992

Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clinical Endocrinology 64(5): 542-548, 2006